Bladder Cancer
Phase 3 trials of nonsurgical therapy for low-grade bladder cancer meet primary endpoints
Two phase 3 trials that evaluated a nonsurgical therapy for certain patients with bladder cancer met their primary endpoints, according to the agent’s manufacturer.
Agent Orange exposure linked to increased risk for bladder cancer among Vietnam veterans
Men exposed to Agent Orange during their military service had a modestly increased risk for bladder cancer, results of a retrospective study of Vietnam veterans showed.
Y chromosome loss may be key to unlocking more effective bladder cancer treatment for men
A series of studies showed that loss of the Y chromosome helps cancer evade the body’s immune system response, resulting in more aggressive bladder cancer in men as they age.
Bladder cancer therapy with BCG vaccine may reduce risk for Alzheimer’s, related dementias
The BCG vaccine appeared associated with a significantly lower rate of and risk for Alzheimer’s disease and related dementias among patients with nonmuscle-invasive bladder cancer, according to data published in JAMA Network Open.
Presence of CVD, especially atherosclerosis, could increase cancer risk
Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.
Amid drug shortage, chemotherapy regimen a viable alternative for high-risk bladder cancer
The combination of gemcitabine and docetaxel conferred superior high-grade recurrence-free survival compared with standard therapy among adults with high-risk nonmuscle-invasive bladder cancer, results of a retrospective study showed.
Pembrolizumab active in non-muscle-invasive bladder cancer unresponsive to BCG
SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.
Trial represents ‘first foray’ into molecularly-guided approach to bladder sparing
A prospective phase 2 trial that evaluated risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer failed to meet a prespecified threshold of noninferiority, according to study results.
‘Intriguing’ data may advance more personalized approach to muscle-invasive bladder cancer
SAN FRANCISCO — Transurethral resection of bladder tumor followed by systemic therapy induced stringently defined clinical complete response among more than 40% of patients with muscle-invasive bladder cancer, according to phase 2 study results.
FDA approves gene therapy for high-risk non-muscle invasive bladder cancer treatment
The FDA has approved a gene therapy treatment for adult patients with high-risk bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, according to a press release.